The primary aim of this trial is to evaluate the efficacy of the ALK house dust mite tablet
given once daily compared to a placebo tablet in the treatment of house dut mite allergic
Additionally the secondary objective of the trial is to evaluate the safety and tolarability
of the ALK house dust mite tablet.
Immunotherapy has been shown to provide therapeutic benefits to subjects with house dust mite
induced allergy. This trial is planned to investigate if clinically relevant improvements in
rhinitis symptoms and with less use of symptomatic medication can be obtained in subjects
with a history of poor didease control despite of use of symptomatic medications.